Deadline: 08-Apr-2026
The Pfizer invites proposals for a competitive grant program targeting improvements in HRRm testing for metastatic castration-sensitive prostate cancer (mCSPC). The program supports projects that optimize testing workflows, integrate germline, tissue, and ctDNA approaches, and enhance equitable access, coordination, and real-world outcomes in clinical practice.
Overview
The Pfizer seeks proposals to address challenges in HRRm testing in the mCSPC setting. This includes testing through germline, tissue-based, or circulating tumor DNA (ctDNA) approaches. The program prioritizes projects that improve workflow efficiency, coordination across testing modalities, and long-term integration into clinical practice.
Program Objectives
-
Optimize HRRm testing across germline, tissue, and ctDNA approaches.
-
Advance equitable and sustainable access to testing.
-
Strengthen integration of testing within multidisciplinary healthcare teams.
-
Evaluate system performance and real-world outcomes through research or implementation science initiatives.
-
Support projects with clear pathways to sustainability beyond Pfizer funding.
Funding Details
-
Grants available: 20,000 CAD – 100,000 CAD per project.
-
Preference for cost-effective projects and collaborations across multiple sponsors or institutions.
-
Projects must demonstrate measurable improvements in healthcare processes and sustainability without ongoing grant support.
Eligible Applicants
-
Canadian-based healthcare institutions, professional schools in medical and allied health disciplines, professional organizations, and government agencies.
-
Organizations must submit applications, not individuals.
-
The Project Lead/Principal Investigator must be formally affiliated with the applying organization.
-
Collaborative projects across departments or institutions are encouraged, with clearly defined roles for all partners.
Compliance and Administration
-
Funding released after execution of a formal agreement and submission of all required documentation.
-
Required documents may include final protocols, ethics approvals, and regulatory clearances.
-
Organizations must be legally able to receive funding directly from Pfizer International, LLC, or risk rescission of the award.
Conclusion
The Pfizer Foundation HRRm Testing Grant Program offers a targeted opportunity to enhance testing accuracy, accessibility, and clinical integration in mCSPC care. By supporting collaborative, cost-effective, and sustainable initiatives, the program seeks to improve patient outcomes, streamline healthcare processes, and advance equitable access to precision oncology testing across Canada.
For more information, visit Pfizer.
